Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
about
Advances in understanding prognosis in myeloma.Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications.N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.Risk Stratification in Multiple Myeloma.Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
P2860
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Age is a prognostic factor eve ...... M experience on 2316 patients.
@en
Age is a prognostic factor eve ...... M experience on 2316 patients.
@nl
type
label
Age is a prognostic factor eve ...... M experience on 2316 patients.
@en
Age is a prognostic factor eve ...... M experience on 2316 patients.
@nl
prefLabel
Age is a prognostic factor eve ...... M experience on 2316 patients.
@en
Age is a prognostic factor eve ...... M experience on 2316 patients.
@nl
P2093
P2860
P50
P1433
P1476
Age is a prognostic factor eve ...... M experience on 2316 patients.
@en
P2093
Anne-Marie Stoppa
Benjamin Hebraud
Brigitte Pegourie
Bruno Royer
Catherine Sebban
Cyrille Hulin
Denis Caillot
Frédérique Orsini-Piocelle
Gerald Marit
Laurence Legros
P2860
P304
P356
10.3324/HAEMATOL.2013.098608
P50
P577
2014-04-11T00:00:00Z